Verified email-pattern data for Correctsequence Therapeutics is currently limited. You can still use the company insights and contact sections below.
CorrectSequence Therapeutics (Correctseq) is a clinical-stage biotech company employing its proprietary transformer base editing (tBE) technology to pioneer next-generation gene editing therapies.
Our leading pipeline candidate, CS-101, utilizing innovative base editor targeting HBG, curing β-hemoglobinopathies, has obtained IND approval from the China NMPA. Clinical data demonstrates its superior performance, indicating significant potential for CS-101 to become a best-in-class gene editing therapy for curing patients with β-hemoglobinopathies.
Proof-of-concept (POC) data in mice for in vivo pipelines using tBE-editing therapies via lipid nanoparticle (LNP) delivery are available, including targets for metabolic dysfunction and associated diseases.
Ex vivo multiplex editing of T cells on multiple targets simultaneously preserved T cell growth and function in vivo compared to non-edited cells, establishing tBE as the ideal gene editing tool for the next-generation cell therapy development.
tBE offers significant advantages in controlling off-target effects and enhancing in vivo editing efficiency, making it ideal for both multiplex editing and precise single-target editing. It is compatible with various delivery system, including ex vivo editing in hematopoietic stem cells (HSCs) and T cells, as well as in vivo editing via LNPs or adeno-associated viruses (AAVs).
We are developing multiple pipeline programs targeting genetic diseases, metabolic disorders, and cardiovascular diseases.
Our focus on biotechnology innovation, research and development underscores our commitment to providing efficient, reliable and safe solution for unmet medical needs.
Company Details
- Employees
- 9
- Founded
- -
- Address
- No.99, Haike Road, Pudong Distrct, Shanghai,shanghai 200120,china
- Industry
- Biotechnology Research
- Website
- https://www.correctsequence.com/
- Keywords
- 성남시.
- HQ
- Shanghai, Shanghai
Correctsequence Therapeutics Questions
CorrectSequence Therapeutics's website is https://www.correctsequence.com/
CorrectSequence Therapeutics's LinkedIn profile is https://cn.linkedin.com/company/correctsequence-therapeutics
CorrectSequence Therapeutics has
9 employees.
View email and phone details for 9
employees at CorrectSequence Therapeutics.
CorrectSequence Therapeutics's industry is
Biotechnology Research
CorrectSequence Therapeutics's top competitors are
Obio,
Vyriad,
Obio Tech,
Ifpma,
Yoltech Therapeutics,
Passage Bio,
Ascidian Therapeutics,
Profoundbio,
Crispr Therapeutics,
Rznomics Inc..
CorrectSequence Therapeutics's categories are Biotechnology Research
CorrectSequence Therapeutics's founding year is 2020
Explore related pages
Related company profiles:
Companies like CorrectSequence Therapeutics
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 10 free credits.
Search the #1 Contact Database
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.